HALEON PLC-ADR (HLN) Stock Price, Forecast & Analysis
NYSE:HLN • US4055521003
HLN Key Statistics, Chart & Performance
The current stock price of HLN is 11.2 USD. In the past month the price increased by 14.64%. In the past year, price increased by 15.35%.
HLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to HLN. When comparing the yearly performance of all stocks, HLN is one of the better performing stocks in the market, outperforming 75.19% of all stocks.
HLN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HLN. HLN has an excellent profitability rating, but there are some minor concerns on its financial health.
HLN Financial Highlights
Over the last trailing twelve months HLN reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 6.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.84% | ||
| ROA | 4.2% | ||
| ROE | 8.92% | ||
| Debt/Equity | 0.53 |
HLN Forecast & Estimates
25 analysts have analysed HLN and the average price target is 12.18 USD. This implies a price increase of 8.72% is expected in the next year compared to the current price of 11.2.
For the next year, analysts expect an EPS growth of 5.72% and a revenue growth -1.32% for HLN
HLN Ownership
HLN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HLN
Company Profile
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
Company Info
HALEON PLC-ADR
Building 5, First Floor, The Heights
Weybridge SURREY GB
Employees: 24000
Phone: 441932822000
HALEON PLC-ADR / HLN FAQ
Can you describe the business of HALEON PLC-ADR?
Haleon Plc engages in the provision of personal healthcare products. The company is headquartered in Weybridge, Surrey and currently employs 24,000 full-time employees. The company went IPO on 2022-07-18. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
Can you provide the latest stock price for HALEON PLC-ADR?
The current stock price of HLN is 11.2 USD. The price increased by 0.36% in the last trading session.
Does HALEON PLC-ADR pay dividends?
HALEON PLC-ADR (HLN) has a dividend yield of 1.67%. The yearly dividend amount is currently 0.17.
What is the ChartMill rating of HALEON PLC-ADR stock?
HLN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is HLN stock listed?
HLN stock is listed on the New York Stock Exchange exchange.
Can you provide the growth outlook for HALEON PLC-ADR?
The Revenue of HALEON PLC-ADR (HLN) is expected to decline by -1.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of HALEON PLC-ADR (HLN) stock?
The outstanding short interest for HALEON PLC-ADR (HLN) is 0.45% of its float.